blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1024803

EP1024803 - FLAVONOIDS FOR CYSTIC FIBROSIS THERAPY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  14.09.2012
Database last updated on 29.03.2025
Most recent event   Tooltip14.09.2012Application deemed to be withdrawnpublished on 17.10.2012  [2012/42]
Applicant(s)For all designated states
Children's Hospital & Research Center at Oakland
747 52nd Street
Oakland, CA 94609-1809 / US
[2010/01]
Former [2000/32]For all designated states
Children's Hospital Medical Center of Northern California
747 Fifty Second Street
Oakland, CA 94609-1809 / US
Inventor(s)01 / FISCHER, Horst, Bernhard
839 Carmel Avenue
Albany, CA 94706 / US
02 / ILLEK, Beate
839 Carmel Avenue
Albany, CA 94706 / US
[2000/32]
Representative(s)Walker, Ross Thomson, et al
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
[N/P]
Former [2012/13]Walker, Ross Thomson, et al
Forrester & Boehmert
SkyGarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2009/47]Walker, Ross Thomson, et al
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Former [2008/44]Gowshall, Jonathan Vallance, et al
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Former [2000/32]Gowshall, Jonathan Vallance, et al
FORRESTER & BOEHMERT Franz-Joseph-Strasse 38
80801 München / DE
Application number, filing date98953609.916.10.1998
[2000/32]
WO1998US21887
Priority number, dateUS1997095191216.10.1997         Original published format: US 951912
[2000/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9918953
Date:22.04.1999
Language:EN
[1999/16]
Type: A1 Application with search report 
No.:EP1024803
Date:09.08.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 22.04.1999 takes the place of the publication of the European patent application.
[2000/32]
Search report(s)International search report - published on:EP22.04.1999
ClassificationIPC:A61K31/35, A61K31/05, A61K31/375
[2000/32]
CPC:
A61K31/7048 (EP,US); A61K31/05 (EP,US); A61K31/352 (EP,US);
A61K31/375 (EP,US); A61K45/06 (EP,US); A61P11/00 (EP);
A61P3/00 (EP) (-)
C-Set:
A61K31/05, A61K2300/00 (EP,US);
A61K31/352, A61K2300/00 (US,EP);
A61K31/375, A61K2300/00 (US,EP);
A61K31/7048, A61K2300/00 (US,EP)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/32]
TitleGerman:FLAVONOIDEN ZUR BEHANDLUNG VON ZYSTISCHER FIBROSE[2000/32]
English:FLAVONOIDS FOR CYSTIC FIBROSIS THERAPY[2000/32]
French:FLAVONOIDES SERVANT AU TRAITEMENT DE LA MUCOVISCIDOSE[2000/32]
Entry into regional phase16.05.2000National basic fee paid 
16.05.2000Designation fee(s) paid 
16.05.2000Examination fee paid 
Examination procedure17.05.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
16.05.2000Examination requested  [2000/32]
19.06.2001Despatch of a communication from the examining division (Time limit: M06)
21.12.2001Reply to a communication from the examining division
18.11.2003Despatch of a communication from the examining division (Time limit: M06)
01.04.2004Reply to a communication from the examining division
21.07.2005Cancellation of oral proceeding that was planned for 22.07.2005
21.07.2005Minutes of oral proceedings despatched
22.07.2005Date of oral proceedings (cancelled)
03.05.2007Despatch of communication that the application is refused, reason: substantive examination {1}
24.02.2012Despatch of a communication from the examining division (Time limit: M04)
01.05.2012Application deemed to be withdrawn, date of legal effect  [2012/42]
04.06.2012Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2012/42]
Appeal following examination03.07.2007Appeal received No.  T2023/07
11.09.2007Statement of grounds filed
22.12.2010Result of appeal procedure: continuation of examination procedure
Divisional application(s)EP05015773.4
EP05017863.1  / EP1669067
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.06.2001
Fees paidRenewal fee
04.10.2000Renewal fee patent year 03
22.10.2001Renewal fee patent year 04
21.10.2002Renewal fee patent year 05
23.10.2003Renewal fee patent year 06
03.12.2004Renewal fee patent year 07
27.10.2005Renewal fee patent year 08
27.10.2006Renewal fee patent year 09
29.10.2007Renewal fee patent year 10
27.10.2008Renewal fee patent year 11
26.10.2009Renewal fee patent year 12
25.10.2010Renewal fee patent year 13
Penalty fee
Additional fee for renewal fee
31.10.200407   M06   Fee paid on   03.12.2004
31.10.201114   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]JPS6253923  ;
 [X]JPH05236910  ;
 [X]RU2008015  ;
 [X]JPH0759548  ;
 [XY]  - HWANG ET AL., "Genistein potentiates wild-type and deltaF508-CFTR channel activity", AMERICAN JOURNAL OF PHYSIOLOGY, (199709), vol. 273, no. 3 Part 1, pages C988 - C998, XP002093436 [X] 1-3,5-13,24-26 * page C997, column 2 * [Y] 14,16-23,27-29,51,52,57
 [XY]  - SCOTT ET AL, "Ascorbic acid stimulates chloride transport in the amphibian cornea", INVESTIGATIVE OPHTALMOLOGY, (197510), vol. 14, no. 10, pages 763 - 766, XP002093437 [X] 4,15 * table 1 * [Y] 21-23,29,57
 [Y]  - SMITH, "Treatment of cystic fibrosis based on understanding CFTR", J. INHER. METAB. DIS., (1995), vol. 18, pages 508 - 516, XP002064542 [Y] 14,16-20,27,51,52 * see page 510 "Restoration of trafficking of mutant CFTR" *

DOI:   http://dx.doi.org/10.1007/BF00710062
 [YP]  - RUBENSTEIN ET AL., "In vitro pharmacologic restoration of CFTR-mediated chloride transport...", JOURNAL OF CLINICAL INVESTIGATION, (199711), vol. 100, no. 10, pages 2457 - 2465, XP002076381 [YP] 14,16-19,27,51,52 * see page 2464 "Conclusions" *

DOI:   http://dx.doi.org/10.1172/JCI119788
 [Y]  - RANDELL BROWN ET AL., "Chemical chaperones correct the mutant phenotype of the deltaF508 cystic fibrosis...", CELL STRESS & CHAPERONES, (1996), vol. 1, no. 2, pages 117 - 125, XP002093438 [Y] 18,20,28,51,52 * abstract * * see "Discussion" *

DOI:   http://dx.doi.org/10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2
 [X]  - DATABASE WPI, 1, Derwent World Patents Index, vol. 87, no. 15, Database accession no. 87-105816, XP002093439 & JPS6253923 A 19870309 (TEIJIN LTD.) [X] 54 * abstract *
 [X]  - DATABASE WPI, 1, Derwent World Patents Index, vol. 93, no. 42, Database accession no. 93-330545, XP002093440 & JPH05236910 A 19930917 (NISSHIN FLOUR MILLING CO.) [X] 57 * abstract *
 [X]  - DATABASE WPI, 1, Derwent World Patents Index, vol. 94, no. 34, Database accession no. 94-277493, XP002093441 & RU2008015 C 19940228 (MAKSYUTINA) [X] 57 * abstract *
 [X]  - DATABASE WPI, 1, Derwent World Patents Index, vol. 95, no. 18, Database accession no. 95-135875, XP002093442 & JPH0759548 A 19950307 (YAEGAKI HAKKO GIKEN KK) [X] 57 * abstract *
 [A]  - SHEPPARD ET AL., "Mutations in CFTR associated with mild-disease-form chloride channels with altered pore properties", NATURE, (19930311), vol. 362, pages 160 - 164, XP000612158 [A] * the whole document *

DOI:   http://dx.doi.org/10.1038/362160a0
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.